CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

Felip et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d99f61a1d151c65f6849c6 — DOI: https://doi.org/10.1016/j.ejca.2019.11.019

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel· 2004 · 162 citations
2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates· 2010 · 2,928 citations
3. Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials· 2012 · 34 citations
4. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy· 2004 · 2,429 citations
5. SEER Cancer Statistics Review, 1975-2003· 2006 · 11,477 citations